4-(N,N-dimethylaminobutyryloxy)-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide hydrochloride | 1019202-11-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 4-(N,N-dimethylaminobutyryloxy)-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide hydrochloride
• 英文别名: 4-N,N-dimethylaminobutyryloxy-2-methyl-N-2-pyridinyl-2H,1,2-benzothiazine-3-carboxamide-1,1-dioxide hydrochloride；4-(N,N-dimethylamino)butyryloxy-2-methyl-N-(2-pyridinyl)-2H,1,2-benzothiazine-3-carboxamide 1,1-dioxide hydrochloride；4-(N,N-dimethylamino)butyryloxy-2-methyl-N-pyridin-2-yl-2H,1,2-benzothiazine-3-carboxamide 1,1-dioxide hydrochloride；[2-Methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1lambda6,2-benzothiazin-4-yl] 4-(dimethylamino)butanoate;hydrochloride；[2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1λ6,2-benzothiazin-4-yl] 4-(dimethylamino)butanoate;hydrochloride
• CAS: 1019202-11-9
• 化学式: C₂₁H₂₄N₄O₅S*ClH
• 分子量: 480.972
• InChiKey: MNHAOTMDZTYUCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.33
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  吡罗昔康 、 4-(dimethylamino)butanoyl chloride hydrochloride 在 碳酸氢钠 、 盐酸 作用下， 以 水 、 丙酮 为溶剂， 反应 3.0h， 以83.2%的产率得到4-(N,N-dimethylaminobutyryloxy)-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide hydrochloride
  参考文献：
  名称：

  具有快速皮肤穿透速度的带正电荷的水溶性 的昔康及其相关化合物的前药

  摘要：

  通式(1)“结构式1”中新型的带有正电荷的昔康及其相关化合物的前药已被设计并合成。这些前药分子中带正电荷的氨基不仅大大提高了药物的溶解度，而且可以与生物膜的磷酸盐端基负电荷键合，推动前药分子进入细胞质。结果表明前药透过人类皮肤的速度比昔康及其相关化合物快近100倍。口服昔康及其相关化合物后1‑2小时血浆药物浓度达到峰值，而这些前药透皮给药时只需要50分钟左右血浆药物浓度即可达到峰值。在血浆中，超过90％的前药能在几分钟内回到母药结构。这些前药可用于治疗人或动物的任何昔康可治疗的状态。第二，在治疗中，该前药不仅可以口服还可以通过透皮给药，避免了昔康的大多数副作用。通过这些前药的控释透皮给药系统可以使血液中昔康及其相关化合物的浓度稳定在最佳治疗血药浓度，提升疗效并减少昔康及其相关化合物产生的副作用。这些前药透皮给药的另一大好处是给药更加方便，特别是对儿童给药。

  公开号：

  CN103980228B

文献信息

• HIGH PENETRATION COMPOSITIONS AND USES THEREOF
  申请人：Yu Chongxi

  公开号：US20090238763A1

  公开（公告）日：2009-09-24

  The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for non-steroidal anti-inflammatory agents (NSAIAs), which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate.

  本发明涉及新型高渗透性组合物或高渗透性前药（HPP）的组成和用途，特别是用于非甾体抗炎药（NSAIAs）的HPP，其能够高效地穿过生物屏障。这里的HPP能够在穿过生物屏障后转化为父活性药物或药物代谢物，从而可以治疗与父药物或代谢物相关的疾病。此外，由于能够穿过生物屏障，这里的HPP能够到达父药物可能无法进入或无法在目标区域产生足够浓度的区域，从而提供新的治疗方法。这里的HPP可以通过各种给药途径给予受试者。例如，由于其穿透生物屏障的能力，HPP可以在局部给药到疾病作用部位并以高浓度存在，从而避免系统性给药的需要。另一个例子是，这里的HPP可以被系统性地给药到生物体内，并以更快的速率进入循环系统。
• WO2008/44095
  申请人：——

  公开号：——

  公开（公告）日：——
• PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES
  申请人：Techfields Inc

  公开号：EP2170826B1

  公开（公告）日：2022-04-27
• HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS
  申请人：Yu Chongxi

  公开号：US20110269689A1

  公开（公告）日：2011-11-03

  High penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capable of being converted to parent drugs or parent drug-related compounds such as metabolites after crossing one or more biological barriers and thus can render treatments for the conditions that the parent drugs or parent drug-related compounds can. Additionally, the HPCs are capable of reaching areas that their parent drugs or parent drug-related compounds may not be able to access or to render a sufficient concentration at the target areas HPCs of NSAIA, for example, have demonstrated indications such as treating hair loss. A HPC can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
• US9872846B2
  申请人：——

  公开号：US9872846B2

  公开（公告）日：2018-01-23